Pharming Group (XAMS:PHARM) Net Margin %: -7.20% (As of Mar. 2026)


XAMS:PHARM Pharming Group XAMS:PHARM
80 GF Score
Price €1.15
GF Value €1.26
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Net Margin %?

Pharming Group XAMS:PHARM -0.82% 80 Net Margin % is -7.20% as of Mar. 2026. GuruFocus rates XAMS:PHARM with a GF Score™ of 80/100 and a GF Value™ of €1.26 (Fairly Valued). The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Pharming Group ranks better than 74.13% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Pharming Group's Net Income for the three months ended in Mar. 2026 was €-4.5 Mil. Pharming Group's Revenue for the three months ended in Mar. 2026 was €62.7 Mil. Therefore, Pharming Group's net margin for the quarter that ended in Mar. 2026 was -7.20%.

The historical rank and industry rank for Pharming Group's Net Margin % or its related term are showing as below:

XAMS:PHARM' s Net Margin % Range Over the Past 10 Years
Min: -110.48   Med: 3.71   Max: 21.41
Current: 3.32

XAMS:PHARM's Net Margin % is ranked better than
74.13% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs XAMS:PHARM: 3.32

Pharming Group  (XAMS:PHARM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Pharming Group Net Margin % Related Terms

Pharming Group Net Margin % Historical Data

* Premium members only.

The historical data trend for Pharming Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Net Margin % Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.04 6.65 -4.30 -3.98 0.76

Pharming Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.61 5.04 7.76 4.98 -7.20

XAMS:PHARM vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Pharming Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Pharming Group's Net Margin % falls into.


XAMS:PHARM
80GF Score
Pharming Group XAMS:PHARM
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Pharming Group's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=2.435/321.218
=0.76 %

Pharming Group's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.509/62.667
=-7.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -7.20% mean?
Pharming Group (XAMS:PHARM) has a Net Margin % of -7.20% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pharming Group and its competitors. According to the industry distribution chart, Pharming Group ranks #245 out of 947 companies in the Biotechnology industry, placing it in the top 25.9%.
Is Pharming Group's Net Margin % too high?
Pharming Group's current Net Margin % is -7.20%. Based on the distribution chart, Pharming Group ranks #245 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharming Group has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #245 out of 947 companies for Net Margin %. This puts Pharming Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pharming Group and its competitors. Pharming Group's current Net Margin % is -7.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (XAMS:PHARM) is currently considered Fairly Valued. The stock's GF Value™ is €1.26, compared to a current price of €1.15 — trading 8.8% below its estimated fair value. The current Net Margin % is -7.20%. Pharming Group's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pharming Group (XAMS:PHARM), the current Net Margin % is -7.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (XAMS:PHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €1.15 is trading 8.8% below its estimated GF Value™ of €1.26. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for XAMS:PHARM:

  • Net Margin %: -7.20%
  • GF Value™: €1.26 vs. price of €1.15 (8.8% below fair value)
  • GF Score™: 80/100 with 1 warning sign

No single metric tells the full story. See the XAMS:PHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
80GF Score

Get the complete analysis for XAMS:PHARM

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.15
Price
€1.26
GF Value